Case Report

Early Aggressive Immunotherapy Improves Functional Outcome in Chronic Immune Sensory Polyradiculopathy

Jasmine Shimin Koh, James Wei Min Tung, Genevieve Lynn Yu Tan-Yu, and Thirugnanam Umapathi

1Department of Neurology, National Neuroscience Institute, 11 Jalan Tan Tock Seng, Singapore, 308433
2Lee Kong Chian School of Medicine, Nanyang Technological University, 59 Nanyang Dr., Experimental Medicine Building, Singapore, 636921

Correspondence should be addressed to Jasmine Shimin Koh; jasmine.koh.s.m@singhealth.com.sg

Received 9 November 2019; Revised 22 January 2020; Accepted 28 January 2020; Published 21 February 2020

1. Introduction

First described by Sinnreich et al. in 2004 [1], chronic immune sensory polyradiculopathy (CISP) is an uncommon and probably underrecognized cause of peripheral sensory ataxia affecting the sensory nerve roots proximal to the dorsal root ganglion (DRG). Though some patients may have concomitant involvement of the proximal motor nerve roots and are termed chronic immune sensorimotor polyradiculopathy (CISMP) [2–5], others have disease strictly confined to the proximal sensory nerve roots. Publications related to CISP [6–8] remain rare and limited since the entity was first described. Here, we describe a case report of an elderly man who was diagnosed with CISP and improved remarkably only after several courses of combination immunotherapy, emphasizing the importance of prompt recognition and aggressive treatment.

2. Case Presentation

In this study, we describe an 80-year-old man presented with progressive feet numbness, unsteady gait, and recurrent falls for two weeks. He did not have limb weakness and bladder or bowel disturbance. He had severely impaired lower limb position and vibration sense as well as decreased deep tendon reflexes. Strength was normal, and Babinski’s sign was absent. Cerebellar and cranial nerve examinations were normal. He was unable to stand or walk...
due to severe sensory ataxia. Initial differential diagnoses were sensory neuronopathy, CIDP, and dorsal spinal column pathology. Nerve conduction study (NCS), syphilis and HIV serologies, serum neuronal antibodies (anti-Hu, anti-Yo, anti-Ri, anti-CRMP5, antiambiophyphins, anti-Ma, anti-Ta, anti-SOX-1, and anti-GAD65), extractable nuclear antigen antibodies, vitamin B12, folate, and copper levels were normal. A nonenhanced MR scan of the spine showed normal spinal cord structure and signal and chronic lumbar degenerative changes with osteophyte and disc bulges. This did not explain the patient’s relatively acute sensory ataxia. There was no nerve root thickening, enlargement, or enhancement seen possibly related to not administering contrast for the scan. CT brain showed normal brain parenchyma and cerebellum. Somatosensory evoked potentials (SSEP) and lumbar puncture were subsequently performed. Tibial SSEP (Table 1) revealed absent responses at lumbar, subcortical, and cortical points, suggesting proximal conduction defect and localizing the pathology to the lumbar sensory nerve roots proximal to the dorsal root ganglion. Median SSEP was normal at Erb’s, cervicomedullary, and cortical points. Cerebrospinal fluid (CSF) showed cytoalbuminergic dissociation (nucleated cell 2 cells/μL (reference range 0–5 cells/μL) and protein 0.93 g/L (reference range 0.10–0.40 g/L)), indicative of inflammation. Ganglioside antibodies such as GD1b seen in acute and chronic sensory neuropathy with ataxia were not available. The constellation of clinical features, normal NCS, characteristic SSEP abnormalities, and raised CSF protein prompted a diagnosis of CISP.

Four days after admission, he was given 1 g of intravenous methylprednisolone daily for five days followed by oral prednisolone 1 mg/kg. He did not improve; hence, intravenous immunoglobulins (IVIg) were added at a dose of 0.4 g/kg daily for five days. Mycophenolate mofetil was also started as a steroid-sparing agent while the prednisolone dose was slowly tapered. He made minimal improvement over several weeks and remained functionally impaired. He was treated with another two courses of monthly IVIg before significant improvement in function was observed. Modified Rankin scale (mRS) improved from 4 to 1, while Berg balance score improved from 31/56 to 44/56 (Table 2). A repeat NCS remained normal (Table 3) while tibial SSEP suggested improvement with non-localized slowing (Table 1). Four months after the last IVIg course, he was able to walk independently. He is maintained on mycophenolate mofetil and has been in remission since.

### 3. Discussion

CISP is an immune-mediated inflammation of the proximal sensory nerve roots characterized by peripheral sensory ataxia, normal motor examination, normal motor and sensory NCS, characteristic SSEP abnormalities, raised CSF protein on spinal tap, and thickened nerve roots on MR imaging [1].

Initial symptoms may be asymmetric and start with paresthesia, numbness, or pain of the distal lower limbs.

### Table 1: Initial and repeat tibial somatosensory evoked potentials.

| Waveform       | Initial Left (ms) | Initial Right (ms) | Repeat (four months after treatment) Left (ms) | Repeat (four months after treatment) Right (ms) | Normal reference |
|----------------|-------------------|--------------------|-----------------------------------------------|-----------------------------------------------|-----------------|
| Popliteal fossa | 8.40              | 8.90               | 9.1                                           | 9.1                                           | <22.0           |
| Lumbar point (N21) | Absent | Absent             | Absent                                        | Absent                                        | <22.0           |
| Subcortical (P31) | Absent | Absent             | 32.3                                          | 34.5                                          | <31.6           |
| Cortical (P37)   | Absent            | Absent             | Absent                                        | Absent                                        | <40.2           |

These symptoms gradually worsen and spread proximally to the hips and upper limbs with more symmetric involvement. Duration from symptom onset to medical consult ranges from few months to 18 years [1,6–8]. Neurologic examination indicates large-fibre sensory loss and sensory gait ataxia. Muscle strength is often preserved except in CISP where there is concomitant motor nerve root involvement [2–5].

Histologic findings of three cases from the largest series [1] diagnosed with CISP that underwent lumbar sensory rootlet biopsy showed presence of endoneurial macrophages, lack of degenerating profiles, and features of chronic demyelination and remyelination with numerous onion-bulb formations. These features support primary demyelination of proximal sensory nerve roots, similar to changes observed in the peripheral nerves of patients with CIDP suggesting that CISP may be an additional phenotype along the CIDP spectrum [8–10]. However, unlike CIDP, the distal nerve segments are spared in CISP, as evidenced by normal NCS. Characteristic SSEP abnormalities include absent or delayed proximal lumbar/subcortical responses, while the contrast-enhanced MR scan of the spine could show thickened enhancing nerve roots. Spinal tap typically shows cytoalbuminergic dissociation [1, 6–8].

Through this case, we would like to raise awareness of this treatable immune-mediated condition among physicians and caution against wrongly attributing the sensory ataxia and unsteady gait to a functional gait disorder especially when routine NCS and spine imaging are normal. Prompt recognition in addition to specific evaluation with SSEP, spinal tap, and contrast-enhanced MR scan of the spinal nerve roots will help clinch the diagnosis.

In addition, we emphasize the importance of early and aggressive immunotherapy. The immunopathology in CISP is at the central processes of the spinal sensory nerve roots, proximal to the dorsal root ganglion. Nerve regeneration here is likely to be less robust because of the need to form connections with the central nervous system [11], possibly inhibited by factors such as Nogo-A [12]. Other pathologies at this site, e.g., traumatic nerve root avulsion, likewise have poor regenerative prognosis. Although there are currently no randomized trials to guide treatment in CISP owing to its rarity, we believe the importance of aggressive and early immunotherapy in CISP before Wallerian degeneration is advanced in the spinal column pathology.
sensory nerve roots. Our patient presented early compared with other cases in the literature [1,6,7]. This and the use of combination immunotherapy which has not been described before in CISP, we believe, led to his good and complete recovery after seven months of treatment.

Finally, we suggest incorporating follow-up SSEP in addition to clinical functional scores (mRS and Berg balance scale) to gauge treatment response. Our experience corroborates with a previous report that SSEP may serve as an additional aid for modulation of immunotherapy [7].

4. Conclusion

CISP is a rare and treatable cause of peripheral sensory ataxia. Prompt recognition and early institution of aggressive combination immunotherapy improve functional outcomes.

---

**Table 2: Functional scores in relation to time course and treatment.**

|                                | On admission | 1.5 weeks | 5 weeks | 2.5 months | 4 months | 7 months |
|--------------------------------|--------------|-----------|---------|------------|----------|----------|
| **Immunosuppressant**          |              |           |         |            |          |          |
| Intravenous immunoglobulins (IVIg) |              |           |         |            |          |          |
| Corticosteroids and mycophenolate mofetil |              |           |         |            |          |          |
| **Modified Rankin scale (mRS)** | 4            | 4         | 4       | 4          | 1        | 0        |
| **Berg balance score**         | Not assessed | 31/56     | 34/56   | 39/56      | 44/56    | Not assessed |

**Table 3: Initial and repeat (performed 4 months apart) nerve conduction study parameters.**

| sensory nerve conduction | Right median nerve (antidromic) |  | Right ulnar nerve (antidromic) |  |  |
|--------------------------|---------------------------------|---|-------------------------------|---|---|
|                          | Initial | Repeat | Normal limit* | Initial | Repeat | Normal limit* |
| Peak latency (ms)        | 3.6     | 3.2    | <3.9 | 3.0 | 3.0 | <3.0 |
| Amplitude (µV)           | 35      | 26     | >14  | 20  | 23  | >9.0 |
| Velocity (m/s)           | 50      | 55     | >50  | 50  | 51  | >50  |
| Right sural (antidromic) | Initial | Repeat | Normal limit* | Initial | Repeat |
| Peak latency (ms)        | 3.8     | 3.7    | <4.5 |     |    |    |
| Amplitude (µV)           | 7       | 8      | >7.0 |     |    |    |
| Velocity (m/s)           | 48      | 49     | >40  |     |    |    |

**Motor nerve conduction**

| Motor nerve conduction | Right median nerve (antidromic) |  | Right ulnar nerve (antidromic) |  |  |
|------------------------|---------------------------------|---|-------------------------------|---|---|
|                        | Initial | Repeat | Normal limit* | Initial | Repeat | Normal limit* |
| Distal latency (ms)    | 3.7     | —      | <4.5 | 2.9 | — | <3.0 |
| Amplitudes (mV) (distal/proximal) | 7.7/6.6 | — | >5.5 | 11.1/9.5 | — | >7.0 |
| Velocity (m/s)         | 50      | —      | >50  | 56  | — | >50  |
| F-wave latency (ms)    | 26.2    | —      | 22–32 | 27.4 | — | 21–29 |
| Right tibial nerve (antidromic) | Initial | Repeat | Normal limit* | Initial | Repeat | Normal limit* |
| Distal latency (ms)    | 4.6     | —      | <4.6 |     |    |    |
| Amplitudes (mV) (distal/proximal) | 8.7/7.9 | — | >5.0 |     |    |    |
| Velocity (m/s)         | 40      | —      | >42  |     |    |    |
| F-wave latency (ms)    | 47.8    | —      | 38–52 |     |    |    |

*Normative data derived from 245 age-height matched controls; ^measurements following stimulation at the wrist/antecubital fossa for median nerve, at the wrist/above elbow for ulnar nerve, and at the ankle/popliteal fossa for tibial nerve; repeat motor nerve conduction study was not performed as the patient had no motor deficits.
Consent

Written informed consent was obtained from the patient.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

Authors’ Contributions

All authors had access to data and a role in writing the manuscript.

References

[1] M. Sinnreich, C. J. Klein, J. R. Daube, J. Engelstad, R. J. Spinner, and P. J. B. Dyck, "Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia," *Neurology*, vol. 63, no. 9, pp. 1662–1669, 2004.

[2] S. Khadilkar, B. Patel, K. A. Mansukhani, and S. Jaggi, "Two cases of chronic immune sensorimotor polyradiculopathy: expanding the spectrum of chronic immune polyradiculopathies," *Muscle & Nerve*, vol. 55, no. 1, pp. 135–137, 2017.

[3] T. Thammongkolchai, O. Suhaib, P. Termsarasab, Y. Li, and B. Katirji, "Chronic immune sensorimotor polyradiculopathy: report of a case series," *Muscle & Nerve*, vol. 59, no. 6, pp. 658–664, 2019.

[4] R. Rojas-Garcia, E. Gallardo, C. De La Torre, L. Sanvito, and I. Illa, "Chronic sensorimotor polyradiculopathy with antibodies to P2: an electrophysiological and immunoproteomic analysis," *Muscle and Nerve*, vol. 38, no. 1, pp. 933–938, 2008.

[5] C. M. Caporale, C. Staedler, C. Gobbi, C. L. Bassetti, and A. Uncini, "Chronic inflammatory lumbosacral polyradiculopathy: a regional variant of CIDP," *Muscle & Nerve*, vol. 44, no. 5, pp. 833–837, 2011.

[6] S. A. Trip, T. Saifee, W. Honan et al., "Chronic immune sensory polyradiculopathy with cranial and peripheral nerve involvement," *Journal of Neurology*, vol. 259, no. 6, pp. 1238–1240, 2012.

[7] A. M. Clerici, E. Nobile-Orazio, M. Mauri, F. S. Squellati, and G. G. Bono, "Utility of somatosensory evoked potentials in the assessment of response to IVIG in a long-lasting case of chronic immune sensory polyradiculopathy," *BMC Neurology*, vol. 17, no. 1, pp. 1–8, 2017.

[8] S. Khadilkar, P. Dhome, and S. Deshmukh, "Chronic dysimmune neuropathies: beyond chronic demyelinating polyradiculoneuropathy," *Annals of Indian Academy of Neurology*, vol. 14, no. 2, pp. 81–92, 2011.

[9] E. K. O’Ferrall, D. Gendron, M. C. Guiot, J. Hall, and M. Sinnreich, "Lower motor neuron syndrome due to cauda equina hypertrophy with onion bulbs," *Muscle and Nerve*, vol. 48, no. 2, pp. 301–305, 2013.

[10] X. Ayrignac, K. Viala, R. M. Koutidis et al., "Sensory chronic inflammatory demyelinating polyneuropathy: an under-recognized entity?" *Muscle & Nerve*, vol. 48, no. 5, pp. 727–732, 2013.

[11] P. K. Thomas, "Selective vulnerability of the centrifugal and centripetal axons of primary sensory neurons," *Muscle and Nerve*, vol. 5, no. 95, pp. S117–S121, 1982.

[12] A. B. Huber and M. E. Schwab, "Nogo-A, a potent inhibitor of neurite outgrowth and regeneration," *Biological Chemistry*, vol. 381, no. 5-6, pp. 407–419, 2000.